Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 44

Sort by

Sort Order Select

Journal Articles

Molecular classification improves risk assessment in adult BCR-ABL1– negative B-ALL

Blood (2021) 138 (11): 948–958.

https://doi.org/10.1182/blood.2020010144

Published: 2021

Includes: Supplemental data

Journal Articles

Young Adults Presenting with Extramedullary Acute Myeloid Leukemia Have A Unique Sensitivity to High Doses of Anthracyclines: Subset Analysis of ECOG 1900,

Hugo F. Fernandez, MD, Zhuoxin Sun, PhD, Mark R. Litzow, MD, Selina M. Luger, MD, Elisabeth Paietta, PhD, Janis Racevskis, PhD, Gordon W. Dewald, PhD, PhD, FACMG, Rhett P Ketterling, MD, John M. Bennett, MD, Jacob M. Rowe, MD, Hillard M. Lazarus, MD, FACP, Martin S. Tallman, MD

Blood (2011) 118 (21): 3619.

https://doi.org/10.1182/blood.V118.21.3619.3619

Published: 2011

Journal Articles

Autologous Hematopoietic Cell Transplantation as Consolidation for Younger Patients with Acute Myeloid Leukemia in First Complete Remission: Follow-up of E1900.

Hugo F. Fernandez, MD, Zhuoxin Sun, Ph.D, Mark R. Litzow, Selina M. Luger, MD, Elisabeth M. Paietta, Gordon W. Dewald, Rhett P. Ketterling, MD, John M Bennett, Jacob M. Rowe, MD, Hillard M. Lazarus, MD, Martin S. Tallman, MD

Blood (2009) 114 (22): 3405.

https://doi.org/10.1182/blood.V114.22.3405.3405

Published: 2009

Journal Articles

Validation of CLL FISH Panel Scoring by Members of the Chronic Lymphocytic Leukemia Research Consortium.

Stephanie A. Smoley, Daniel L. Van Dyke, Neil E. Kay, Nyla A. Heerema, Marie L. dell’ Aquila, Prasad Koduru, Paola Dal Cin, Laura Rassenti, John C. Byrd, Kanti R. Rai, Jennifer R. Brown, Andrew W Greaves, Thomas J. Kipps, Gordon W. Dewald

Blood (2008) 112 (11): 1067.

https://doi.org/10.1182/blood.V112.11.1067.1067

Published: 2008

Journal Articles

Standard Consolidation/Maintenance Chemotherapy Is Consistently Superior to a Single Autologous Transplant for Adult Patients with Acute Lymphoblastic Leukemia: Results of the International ALL Trial (MRC UKALL XII/ECOG E2993)

Jacob M. Rowe, MD, Georgina Buck, Anthony V Moorman, MD, Martin S Tallman, MD, Susan M Richards, Ph.D, Adele K Fielding, MD, Ph.D, Alan K. Burnett, MD, FRCP, Ian M Franklin, MD, Peter H. Wiernik, MD, Hillard M Lazarus, MD, Elisabeth Paietta, PhD, Mark R. Litzow, MD, David I Marks, MD, Selina Luger, MD, Gordon W. Dewald, PhD, PhD, FACMG, Anthony H. Goldstone, FRCP, FRCPath

Blood (2008) 112 (11): 3314.

https://doi.org/10.1182/blood.V112.11.3314.3314

Published: 2008

Journal Articles

Implications for the Use of Monoclonal Antibodies in Future Adult ALL Trials: Analysis of Antigen Expression in 505 B-Lineage (B-Lin) ALL Patients (pts) on the MRC UKALLXII/ECOG2993 Intergroup Trial.

Elisabeth Paietta, Ph.D., Xiaochun Li, Ph.D., Sue Richards, Janis Racevskis, Ph.D., Gordon W. Dewald, PhD, PhD, FACMG, Jacob M. Rowe, MD, Martin S Tallman, Hillard M Lazarus, MD, Mark Litzow, M.D., Anthony H. Goldstone, FRCP, FRCPath, Peter H. Wiernik, MD

Blood (2008) 112 (11): 1907.

https://doi.org/10.1182/blood.V112.11.1907.1907

Published: 2008

Journal Articles

Outcome in Philadelphia Chromosome Positive (Ph+) Adult ALL Patients (Pts) May Be More Determined by CD25 Expression Than by Ph Status Per Se.

Elisabeth Paietta, Xiaochun Li, Ph.D., Sue Richards, Janis Racevskis, Ph.D., Gordon W. Dewald, PhD, PhD, FACMG, Jacob M. Rowe, MD, Martin S Tallman, Hillard M Lazarus, MD, Mark R. Litzow, MD, Anthony H. Goldstone, FRCP, FRCPath, Peter Wiernik, MD

Blood (2008) 112 (11): 1500.

https://doi.org/10.1182/blood.V112.11.1500.1500

Published: 2008

Journal Articles

Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1–risk myelodysplastic syndromes with karyotypes other than deletion 5q

Azra Raza, James A. Reeves, Eric J. Feldman, Gordon W. Dewald, John M. Bennett, H. Joachim Deeg, Luke Dreisbach, Charles A. Schiffer, Richard M. Stone, Peter L. Greenberg, Peter T. Curtin, Virginia M. Klimek, Jamile M. Shammo, Deborah Thomas, Robert D. Knight, Michele Schmidt, Kenton Wride, Jerome B. Zeldis, Alan F. List

Blood (2008) 111 (1): 86–93.

https://doi.org/10.1182/blood-2007-01-068833

Published: 2008

Includes: Supplemental data

Journal Articles

Peripheral Blood Cytogenetic Studies in Hematological Neoplasms: Predictors of Obtaining Metaphases for Analysis.

Kebede Hussein, MD, Rhett P. Ketterling, MD, Gordon W. Dewald, PhD, Rachael L. Hulshizer, Daniel G. Kuffel, Anne E. Wiktor, Daniel L. Van Dyke, PhD, Ayalew Tefferi, MD

Blood (2007) 110 (11): 3504.

https://doi.org/10.1182/blood.V110.11.3504.3504

Published: 2007

Journal Articles

Peripheral Blood Cytogenetic Studies in Myelofibrosis: Overall Yield and Comparison with Bone Marrow Cytogenetic Studies

Kebede Hussein, MD, Rhett P. Ketterling, MD, Gordon W. Dewald, PhD, Daniel L. Van Dyke, PhD, Ruben Mesa, MD, Ayalew Tefferi, MD

Blood (2007) 110 (11): 1547.

https://doi.org/10.1182/blood.V110.11.1547.1547

Published: 2007

Journal Articles

Impact of cytogenetics on outcome of matched unrelated donor hematopoietic stem cell transplantation for acute myeloid leukemia in first or second complete remission

Martin S. Tallman, Gordon W. Dewald, Sharavi Gandham, Brent R. Logan, Armand Keating, Hillard M. Lazarus, Mark R. Litzow, Jayesh Mehta, Tanya Pedersen, Waleska S. Pérez, Jacob M. Rowe, Meir Wetzler, Daniel J. Weisdorf

Blood (2007) 110 (1): 409–417.

https://doi.org/10.1182/blood-2006-10-043299

Published: 2007

Journal Articles

Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial

Anthony V. Moorman, Christine J. Harrison, Georgina A. N. Buck, Sue M. Richards, Lorna M. Secker-Walker, Mary Martineau, Gail H. Vance, Athena M. Cherry, Rodney R. Higgins, Adele K. Fielding, Letizia Foroni, Elisabeth Paietta, Martin S. Tallman, Mark R. Litzow, Peter H. Wiernik, Jacob M. Rowe, Anthony H. Goldstone, Gordon W. Dewald, on behalf of the Medical Research Council (MRC)/National Cancer Research Institute (NCRI) Adult Leukaemia Working Party of the United Kingdom and the Eastern Cooperative Oncology Group

Blood (2006) 109 (8): 3189–3197.

https://doi.org/10.1182/blood-2006-10-051912

Published: 2006

Includes: Supplemental data

Journal Articles

Alemtuzumab and Rituximab for Therapy of Patents with Early Stage High Risk CLL: Report of a Planned Interim Analysis.

Clive S. Zent, MD, Nancy D. Bone, Timothy G. Call, MD, Tait D. Shanafelt, MD, Susan M. Geyer, PhD, Charla R. Secreto, Diane F. Jelinek, PhD, Gordon W. Dewald, PhD, Neil E. Kay, MD

Blood (2006) 108 (11): 2829.

https://doi.org/10.1182/blood.V108.11.2829.2829

Published: 2006

Journal Articles

Expression of Tcl-1 as a Potential Prognostic Factor for Treatment Outcome in B-Cell Chronic Lymphocytic Leukemia.

Rebekah E. Browning, BA, David M. Lucas, PhD, Susan M. Geyer, PhD, Diane F. Jelinek, PhD, Renee C. Tschumper, Timothy G. Call, MD, Tait D. Shanafelt, MD, Clive S. Zent, MD, Nancy D. Bone, Gordon W. Dewald, PhD, Thomas S. Lin, MD, Nyla A. Heerema, PhD, Michael R. Grever, MD, Neil E. Kay, MD, John C. Byrd, MD

Blood (2006) 108 (11): 2792.

https://doi.org/10.1182/blood.V108.11.2792.2792

Published: 2006

Journal Articles

Long Term Clinical Benefit of Lenalidomide (Revlimid) Treatment in Patients with Myelodysplastic Syndrome without Del 5q Cytogenetic Abnormalities.

Azra Raza, MD, James E. Reeves, MD, Eric J. Feldman, MD, H. Joachim Deeg, MD, Luke Dreisbach, MD, Charles A. Schiffer, MD, Jamile M. Shammo, MD, Virginia M. Klimek, MD, Peter L. Greenberg, MD, John M. Bennett, MD, Gordon W. DeWald, PhD, Jerome B. Zeldis, MD, PhD, Kenton Wride, MS, Michele Schmidt, RN,C, Robert D. Knight, MD, Alan F. List, MD

Blood (2006) 108 (11): 250.

https://doi.org/10.1182/blood.V108.11.250.250

Published: 2006

Journal Articles

Long-Term Clinical Benefit of Lenalidomide (Revlimid) Treatment in Patients with Myelodysplastic Syndrome and Chromosome Deletion 5q.

Alan F. List, MD, Gordon W. Dewald, PhD, John M. Bennett, MD, Aristoteles Giagounidis, MD, Azra Raza, MD, Eric J. Feldman, MD, Bayard L. Powell, MD, Peter L. Greenberg, MD, Stephen D. Nimer, MD, Jerome B. Zeldis, MD, PhD, Kenton Wride, MS, Michele Schmidt, RNC, Robert D. Knight, MD

Blood (2006) 108 (11): 251.

https://doi.org/10.1182/blood.V108.11.251.251

Published: 2006

Journal Articles

Prognostic Importance of CD49d Expression in Chronic Lymphocytic Leukemia.

Tait D. Shanafelt, MD, Nancy D. Bone, Susan M. Geyer, PhD, Betsy LaPlant, Thomas E. Witzig, MD, Susan Schwager, Gordon W. Dewald, PhD, Greg S. Nowakowski, MD, Renee C. Tschumper, MD, Clive S. Zent, MD, Timothy G. Call, MD, Diane F. Jelinek, PhD, Neil E. Kay, MD

Blood (2006) 108 (11): 2776.

https://doi.org/10.1182/blood.V108.11.2776.2776

Published: 2006

Journal Articles

Additional Cytogenetic Abnormalities and/or Philadelphia Chromosome Metaphase Mosaicism Might Adversely Influence Survival and Imatinib Response in Chronic Myeloid Leukemia.

Andrew P. Landstrom, BS, Rhett P. Ketterling, M.D., Ryan A. Knudson, B.A., Gordon W. Dewald, Ph.D., Ayalew Tefferi, M.D.

Blood (2006) 108 (11): 4783.

https://doi.org/10.1182/blood.V108.11.4783.4783

Published: 2006

Journal Articles

Frequency, Hematopathology and Detection of a New Isodicentric Variant of Deletion 20q.

Stephanie R. Fink, Stephanie A. Smoley, Sarah F. Paternoster, Kimberly J. Stockero, Lai P. Nguyen, Phuong L. Nguyen, M.D., Curtis A. Hanson, M.D., Gordon W. Dewald, Ph.D.

Blood (2006) 108 (11): 4843.

https://doi.org/10.1182/blood.V108.11.4843.4843

Published: 2006

Journal Articles

Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia

Neil E. Kay, Susan M. Geyer, Timothy G. Call, Tait D. Shanafelt, Clive S. Zent, Diane F. Jelinek, Renee Tschumper, Nancy D. Bone, Gordon W. Dewald, Thomas S. Lin, Nyla A. Heerema, Lisa Smith, Michael R. Grever, John C. Byrd

Blood (2006) 109 (2): 405–411.

https://doi.org/10.1182/blood-2006-07-033274

Published: 2006

NARROW

Molecular classification improves risk assessment in adult BCR-ABL1– negative B-ALL

Young Adults Presenting with Extramedullary Acute Myeloid Leukemia Have A Unique Sensitivity to High Doses of Anthracyclines: Subset Analysis of ECOG 1900,

Autologous Hematopoietic Cell Transplantation as Consolidation for Younger Patients with Acute Myeloid Leukemia in First Complete Remission: Follow-up of E1900.

Validation of CLL FISH Panel Scoring by Members of the Chronic Lymphocytic Leukemia Research Consortium.

Standard Consolidation/Maintenance Chemotherapy Is Consistently Superior to a Single Autologous Transplant for Adult Patients with Acute Lymphoblastic Leukemia: Results of the International ALL Trial (MRC UKALL XII/ECOG E2993)

Implications for the Use of Monoclonal Antibodies in Future Adult ALL Trials: Analysis of Antigen Expression in 505 B-Lineage (B-Lin) ALL Patients (pts) on the MRC UKALLXII/ECOG2993 Intergroup Trial.

Outcome in Philadelphia Chromosome Positive (Ph+) Adult ALL Patients (Pts) May Be More Determined by CD25 Expression Than by Ph Status Per Se.

Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1–risk myelodysplastic syndromes with karyotypes other than deletion 5q

Peripheral Blood Cytogenetic Studies in Hematological Neoplasms: Predictors of Obtaining Metaphases for Analysis.

Peripheral Blood Cytogenetic Studies in Myelofibrosis: Overall Yield and Comparison with Bone Marrow Cytogenetic Studies

Impact of cytogenetics on outcome of matched unrelated donor hematopoietic stem cell transplantation for acute myeloid leukemia in first or second complete remission

Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial

Alemtuzumab and Rituximab for Therapy of Patents with Early Stage High Risk CLL: Report of a Planned Interim Analysis.

Expression of Tcl-1 as a Potential Prognostic Factor for Treatment Outcome in B-Cell Chronic Lymphocytic Leukemia.

Long Term Clinical Benefit of Lenalidomide (Revlimid) Treatment in Patients with Myelodysplastic Syndrome without Del 5q Cytogenetic Abnormalities.

Long-Term Clinical Benefit of Lenalidomide (Revlimid) Treatment in Patients with Myelodysplastic Syndrome and Chromosome Deletion 5q.

Prognostic Importance of CD49d Expression in Chronic Lymphocytic Leukemia.

Additional Cytogenetic Abnormalities and/or Philadelphia Chromosome Metaphase Mosaicism Might Adversely Influence Survival and Imatinib Response in Chronic Myeloid Leukemia.

Frequency, Hematopathology and Detection of a New Isodicentric Variant of Deletion 20q.

Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only